|Bid||0.0000 x 28000|
|Ask||0.0000 x 4000|
|Day's Range||1.0300 - 1.0927|
|52 Week Range||0.3800 - 2.3400|
|Beta (5Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 16, 2021 - Aug 20, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.
SAN DIEGO, Jun 14, 2021--Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent the below letter to stockholders. The letter has been signed by all five members of the Company’s Board of Directors: Howard C. Birndorf, Roshawn Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]